A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Histologically or cytologically confirmed locally advanced or metastatic solidtumors with a high prevalence of mucin-1 (MUC1) expression

• At least 1 measurable lesion per RECIST v1.1

• Stable Eastern Cooperative Oncology Group Performance Status of ≤ 1

• Adequate organ function

• Willing to use a highly effective method of birth control

Exclusion Criteria:

• History of prior ≥ Grade 3 Cytokine Release Syndrome (CRS)

• History of severe Infusion-Related Reactions (IRRs), allergic reactions, orhypersensitivity to any ingredients or components of the study treatments

• Infection requiring systemic (oral or intravenous) therapy ≤ 14 days before thefirst dose of study drug(s), or participants with symptomatic COVID-19 infection

• Active leptomeningeal disease or uncontrolled, untreated brain metastasis

• Active autoimmune disease or history of autoimmune disease(s) that may relapse

Note: Other protocol defined Inclusion/Exclusion criteria may apply.